T-Cell Lymphoma
Information
- Disease name
- T-Cell Lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03792256 | Active, not recruiting | Phase 1 | Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) | April 11, 2019 | June 30, 2025 |
| NCT05442554 | Active, not recruiting | Phase 4 | A Study of Brentuximab Vedotin Treatment in Chinese Adults With CD30-Positive Cutaneous T-Cell Lymphoma | July 20, 2023 | September 30, 2024 |
| NCT04712864 | Active, not recruiting | Phase 1 | Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma | September 13, 2021 | December 2025 |
| NCT03952078 | Active, not recruiting | Phase 1 | A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma | May 3, 2019 | April 30, 2026 |
| NCT01181271 | Completed | Phase 2 | Tandem Auto-Allo Transplant for Lymphoma | August 2010 | February 2016 |
| NCT01553786 | Completed | Phase 2 | Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) | November 2011 | March 21, 2019 |
| NCT01777152 | Completed | Phase 3 | ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas | January 31, 2013 | October 2, 2020 |
| NCT01871675 | Completed | Phase 1 | Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies | May 2013 | June 2016 |
| NCT00322985 | Completed | Phase 2 | A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma | June 2006 | July 2014 |
| NCT01902225 | Completed | Phase 1 | Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma | March 4, 2014 | April 11, 2020 |
| NCT01941680 | Completed | High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant | October 31, 2013 | March 2021 | |
| NCT02017613 | Completed | Phase 1 | Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies | November 2013 | May 2016 |
| NCT00001582 | Completed | Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer | June 7, 1997 | March 17, 2023 | |
| NCT02309580 | Completed | Phase 1 | Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma | January 2015 | May 8, 2023 |
| NCT00542919 | Completed | Phase 2 | A Study for Patients With Non-Hodgkin's Lymphomas | November 2007 | February 27, 2018 |
| NCT00161590 | Completed | Phase 1 | Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma | July 2004 | |
| NCT00959686 | Completed | Phase 2 | Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma | September 2009 | February 2013 |
| NCT02424045 | Completed | Phase 2 | Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma | May 2015 | September 2017 |
| NCT02846935 | Completed | Early Phase 1 | p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies | April 25, 2017 | January 22, 2018 |
| NCT03734601 | Completed | Phase 2 | Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation | November 5, 2018 | November 17, 2020 |
| NCT06390319 | Not yet recruiting | Phase 2 | Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) | June 2024 | December 2033 |
| NCT05731375 | Not yet recruiting | Mitochondrial dysfUnction: a Key Player in Doxorubicin-induced Skeletal and Cardiac muscLE Damage | April 2024 | December 2025 | |
| NCT05983965 | Not yet recruiting | Phase 1 | Study of Tazemetostat in Lymphoid Malignancies | August 2024 | December 2029 |
| NCT05978141 | Recruiting | A Registry for People With T-cell Lymphoma | July 27, 2023 | July 27, 2030 | |
| NCT05886478 | Recruiting | A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin | February 8, 2024 | June 30, 2024 | |
| NCT03829540 | Recruiting | Phase 1 | CD4CAR for CD4+ Leukemia and Lymphoma | July 9, 2020 | December 2037 |
| NCT04234048 | Recruiting | Phase 1 | Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | December 18, 2023 | November 2025 |
| NCT04331119 | Recruiting | Phase 2 | Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas | July 23, 2020 | July 31, 2027 |
| NCT05665530 | Recruiting | Phase 1 | A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies | September 12, 2023 | April 2025 |
| NCT05075460 | Recruiting | Phase 3 | Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma | October 1, 2021 | October 30, 2024 |
| NCT05313243 | Recruiting | Phase 2 | Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma | July 10, 2023 | July 30, 2028 |
| NCT02588651 | Recruiting | Phase 2 | A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) | June 17, 2016 | June 15, 2027 |
| NCT06224049 | Recruiting | Early Phase 1 | Treatment of Relapsed or Refractory Epstein-Barr Virus Positive T-cell Lymphoma With hNeo-T | December 1, 2023 | June 30, 2026 |
| NCT06131801 | Recruiting | Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | November 15, 2023 | December 1, 2027 | |
| NCT02086591 | Terminated | Phase 2 | A Phase II Study of Doxycycline in Relapsed NHL | March 2014 | November 2015 |
| NCT00161239 | Terminated | N/A | LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma | February 2005 | October 2007 |
| NCT00893516 | Terminated | Phase 2 | CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma | May 2007 | December 2008 |
| NCT01878708 | Terminated | Early Phase 1 | A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma | July 2013 | February 2017 |
| NCT05387226 | Unknown status | Phase 1 | Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma | May 2022 | December 2023 |
| NCT04264078 | Unknown status | Early Phase 1 | Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies | March 1, 2021 | June 1, 2023 |
| NCT03207789 | Unknown status | T-cell Brazil: Prospective Collection of Data in T-cell Lymphomas Patients | January 1, 2015 | December 31, 2020 | |
| NCT03021057 | Unknown status | Phase 2 | Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas | December 1, 2016 | December 2020 |
| NCT01854112 | Unknown status | Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma | November 2012 |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012190